“wave-life-sciences” Archives

in
Entry Author Date Location
Neurology at Forefront of FDA’s Complex Innovative Trial Design Pilot 04/16/20 National
Bio Roundup: Goodbye Belviq, LogicBio on Hold, Revolution’s IPO & More 02/14/20 National
Wave Life Sciences’ Stumble in Duchenne Leads to 22% Staff Layoff 02/10/20 Boston
Bio Roundup: FDA Approvals, Intrexon’s Shift, Melinta Bankruptcy & More 01/03/20 National
Wave’s Huntington’s Drug Disappoints in Clinical Trial, Stock Sinks 01/02/20 Boulder/Denver
Bio Roundup: Amarin’s Approval, FTC v. Illumina, a $120M Deal & More 12/20/19 National
Triplet Therapeutics Unveils $59M to Try Hairpin Fix for Huntington’s 12/17/19 Boston
Wave Stock Crashes After Decision to Halt Duchenne Drug Studies 12/16/19 Boston
Bio Roundup: Meldonium Slip, Kratom Crackdown, Zinc Fingers & More 02/23/18 National
Wave, Takeda Target RNA Technology at Neuro Diseases With $230M Pact 02/20/18 Boston
East Coast Biotech Roundup: NY Bio, Gender Gap, Zafgen, PureTech & More 05/12/16 Boston
Pfizer Invests in Wave, Inks Metabolic-Focused Drug Development Deal 05/05/16 Boston
With Latest Startup, Harvard’s Verdine Again Aims at Elusive Targets 04/13/16 Boston
WaVe, Voyager Get $170M Combined in Biotech’s Latest IPO Tests 11/11/15 Boston
Selecta, Eyeing IPO, Brings Sanofi, Crossovers Aboard For $38M Round 09/08/15 Boston
New CEO and $80M Later, Syndax Looks Prepped for Second IPO Try 08/24/15 Boston
East Coast Biotech Roundup: WaVe, Shkreli, Intarcia & More 08/21/15 Boston
WaVe Joins the Crossover Party With $66M Series B for RNA Drugs 08/18/15 Boston
WAVE Life Sciences Garners $66,000,000 Series B Funding 08/18/15 Boston
Ex-Alnylam Exec to Steer Warp Drive Bio; Verdine Shifts Roles 03/04/15 Boston
East Coast Biotech Roundup: Hamburg, Merck, Annovation, WaVe & More 02/09/15 Boston
WaVe Life Sciences Garners $18,000,000 Series A Financing Round 02/03/15 Boston
WaVe Gets $18M to Solve RNA’s “Underappreciated” Chemistry Problem 02/02/15 Boston
Page 1 of 1